The GLP-1 rush in India has transformed how people approach weight loss and obesity management. In closed groups and online forums, users compare dosages, swap sourcing tips, and discuss methods of storing low-cost vials. Offline, they walk into clinics asking for the same drug by name: "I want GLP-1." Or, "Which is better... Ozempic or Mounjaro?"
Times have changed from when people had an "injection-phobia and preferred oral medications," says senior endocrinologist Dr V Kumaravel, Madurai-based with the Endocrine Society of Tamil Nadu. "People are now outrightly asking for these drugs by name," he adds.
The GLP-1 Boom: What Fuels the Demand?
This surge persists despite caution from the Union Health Ministry and doctors that GLP-1 drugs—including semaglutide or tirzepatide—are breakthrough products but come with side effects and should not be used indiscriminately. Semaglutide is the active ingredient in Danish company Novo Nordisk's obesity drug Wegovy and diabetes drug Ozempic; tirzepatide is sold by American company Eli Lilly as obesity drug Mounjaro.
The rush accelerated with a burst of generic versions of semaglutide since late March, after the patent expired, allowing local drugmakers to launch over 25 generic brands in vials, reusable pens, and oral tablets. Prices dropped 50 to 80 percent lower than originals like Ozempic, Wegovy, and Rybelsus—from ₹10,000 to ₹17,000 monthly to as low as ₹1,290 (offered by Natco Pharma). Lilly's tirzepatide remains under patent at ₹15,000-₹20,000 but tops the category.
From Clinic Demands to Social Media Hype
The worrying side is demand shaped outside traditional medical settings, doctors warn. "Most people come after seeing Instagram or hearing from someone who has taken it," Dr Kumaravel said. "They come with a fixed agenda of getting one of the GLP-1 drugs. We evaluate whether it is suitable," he added, noting inquiries are "multiple times higher" than prescriptions.
This trend thrives via gyms, "wellness clinics," and peer recommendations online/offline. Social media and forums buzz with advice on sourcing, dose adjustments, side effect management, injection pens, and diets—discussions best held with doctors. Users share before-and-after shots at home, progress records proving efficacy, and even seek prescribers willing to supply or bypass prescriptions, per an investigation.
Obesity Treatment, Not Cosmetic Weight Loss
Before GLP-1 drugs, options for obesity were limited. "There was no drug that could help you lose weight. Doctors advised diet and exercise, but patients came because those weren't working," Dr Kumaravel explained. "In that gap, unregulated remedies emerged, none evidence-based. GLP drugs entered with strong efficacy."
In India, GLP-1 drugs can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists—for BMI ≥25 kg/m² with metabolic risk factors or comorbidities. Obesity is defined as BMI >25 kg/m².
A Mumbai-based GLP-1 user (anonymous) shared: "I got really tired of working hard and still not losing weight... Then I came across how much GLP-1s helped people, especially with PCOS. There are side effects, so I was hesitant. But I've been living with a different set of them anyway. So I decided to pick my struggle."
How GLP-1 Drugs Work: Mechanism Explained
GLP-1 drugs treat obesity and type 2 diabetes by mimicking a naturally occurring hormone that regulates blood sugar and appetite. They increase insulin secretion, reduce glucagon release, slow gastric emptying, and promote satiety, helping patients eat less. Available in India: Semaglutide injection, Semaglutide tablets, Liraglutide, Tirzepatide, Dulaglutide, Exenatide, Exenatide extended release. Market size pegged at ₹5,000 crore.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Side Effects: The Double-Edged Sword
Side effects dominate online discussions but don't deter users. Common ones include nausea, vomiting, bloating, diarrhoea, constipation, tachycardia, dizziness. "Even with awful side effects like insomnia, sulphur burps, and constant diarrhoea, if this is the progress, I'll take it any day," one Mounjaro user posted.
Global authorities caution on serious risks: vision loss, kidney failure, thyroid cancer. "One earlier reported side effect of semaglutide was sudden blindness—non-arteritic anterior ischemic optic neuropathy. With mass usage, people have forgotten," Dr Kumaravel noted. Rapid weight loss risks muscle loss if unmonitored: "You lose not only fat but muscle too. Under supervision, we monitor it."
Apps like Shotlee can help track symptoms, side effects, or medication schedules to discuss accurately with doctors.
Long-Term Concerns: Rebound and Beyond
Even success stories report renewed cravings and weight gain post-discontinuation. Jitendra Chouksey, Founder-CEO of FITTR, says GLP-1s never replace healthy lifestyles. "If truly helping, wouldn't obesity prevalence drop globally? Instead, short-term impact, low adherence, rising obesity."
He cites a recent study showing cardiac health degradation up to 22% in 18 months post-stop, faster than pre-use, questioning "legacy effect" and long-term dependence. "Quick benefits hide long-term effects, like junk food, alcohol, tobacco. Access has expanded beyond medical control."
Doctor's Caution: A Consumer-Driven Market
Dr Kumaravel worries: "The decision has moved from doctor's place to consumer market." Government controls doctors, but "controlling consumers or mob behaviour is harder." Though a "wonder molecule," he's against off-label use—it's a double-edged sword.
What This Means for Patients: Guidance
Who Should Consider GLP-1 Drugs?
- BMI ≥25 with metabolic risks or comorbidities
- Under endocrinologist/internal medicine/cardiologist supervision
- Not for cosmetic/injection-phobic casual use
Talking to Your Doctor
Discuss PCOS, diabetes, obesity history. Compare Ozempic (semaglutide) vs Mounjaro (tirzepatide) efficacy/sides. Monitor muscle loss, heart health. Avoid self-sourcing generics without prescription.
Key Takeaways
- GLP-1 rush driven by generics (₹1,290 vs ₹17,000), social media.
- Strong for obesity/type 2 diabetes, but risks like nausea, blindness, rebound.
- Prescribe only for qualified patients; lifestyle essential.
- Consult doctors, not forums—sustainable health over quick fixes.
The GLP-1 rush highlights innovation but underscores medical guidance for safe use.
